Tag: BRAF inhibitor

1. Vemurafenib plus rituximab treatment was associated with complete response for refractory or relapsed hairy-cell leukemia patients. 2. Post hoc analysis suggested minimal residual disease negative status and the lack of prior v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors exposure were associated with better survival. Evidence Rating Level: 2...
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) and a MEK inhibitor (binimetinib) led to longer overall disease survival in patients with BRAF V600E mutated metastatic colorectal cancer as compared to control groups who received a single...
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) and a MEK inhibitor (binimetinib) led to longer overall disease survival in patients with BRAF V600E mutated metastatic colorectal cancer as compared to control groups who received a single...